Impact of New Drugs for Therapeutic Intervention in Alzheimer’s Disease
Autor
Olloquequi, Jordi
Ettcheto, Miren
Cano, Amanda
Sanchez-López, Elena
Carrasco, Marina
Espinosa, Triana
Beas-Zarate, Carlos
Gudiño-Cabrera, Graciela
Ureña-Guerrero, Monica E.
Verdaguer, Ester
Folch, Jaume
Auladell, Carme
Camins, Antoni
Resumen
The increases in population ageing and growth are leading to a boosting in the number of people living with dementia, Alzheimer’s disease (AD) being the most common cause. In spite of decades of intensive research, no cure for AD has been found yet. However, some treatments that may change disease progression and help control symptoms have been proposed. Beyond the classical hypotheses of AD etiopathogenesis, i.e., amyloid beta peptide (Aβ) accumulation and tau hyperphosphorylation, a trend in attributing a key role to other molecular mechanisms is prompting the study of different therapeutic targets. Hence, drugs designed to modulate inflammation, insulin resistance, synapses, neurogenesis, cardiovascular factors and dysbiosis are shaping a new horizon in AD treatment. Within this frame, an increase in the number of candidate drugs for disease modification treatments is expected, as well as a focus on potential combinatory multidrug strategies.The present review summarizes the latest advances in drugs targeting Aβ and tau as major contributors to AD pathophysiology. In addition, it introduces the most important drugs in clinical studies targeting alternative mechanisms thought to be involved in AD’s neurodegenerative process. Copyright: © 2022 The Author(s).
Colecciones
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Article
A novel rhein-huprine hybrid ameliorates disease-modifying properties in preclinical mice model of Alzheimer’s disease exacerbated with high fat diet (2024)
Espinosa-Jiménez, Triana; Cano, Amanda; Sánchez-López, Elena; Olloquequi, Jordi; Folch, Jaume; Bulló, Mònica; Verdaguer, Ester; Auladell, Carme; Pont, Caterina; Muñoz-Torrero, Diego; ... (BioMed Central Ltd, 2023)Background: Alzheimer’s disease (AD) is characterized by a polyetiological origin. Despite the global burden of AD and the advances made in AD drug research and development, the cure of the disease remains elusive, since ... -
Article
Protein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disorders (2024)
Olloquequi, Jordi; Cano, Amanda; Sanchez-López, Elena; Carrasco, Marina; Verdaguer, Ester; Fortuna, Ana; Folch, Jaume; Bulló, Mònica; Auladell, Carme; Camins, Antoni; ... (Elsevier Masson s.r.l., 2022)Protein tyrosine phosphatase 1B (PTP1B) is a typical member of the PTP family, considered a direct negative regulator of several receptor and receptor-associated tyrosine kinases. This widely localized enzyme has been ... -
Article
Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice (2021)
Ettcheto, Miren; Sánchez-López, Elena; Cano, Amanda; Carrasco, Marina; Herrera, Katherine; Manzine, Patricia Regina; Espinosa-Jiménez, Triana; Busquets, Oriol; Verdaguer, Ester; Olloquequi, Jordi; ... (BioMed Central Ltd, 2021-12)Background: Several studies stablished a relationship between metabolic disturbances and Alzheimer´s disease (AD) where inflammation plays a pivotal role. However, mechanisms involved still remain unclear. In the present ...